Time filter

Source Type

Zhang X.,Shenzhen Futian Hospital of TCM | Nie Y.,Guangzhou University | Li X.,Fourth Peoples Hospital of Shenzhen City Futian Hospital | Wu G.,Fourth Peoples Hospital of Shenzhen City Futian Hospital | And 8 more authors.
Pathology and Oncology Research | Year: 2014

Based on our previous experiments, this study is to further investigate the functional significance of miR-181a and its target gene in gastric cancer. Expression of miR-181a was detected by qRT-PCR in three normal gastric tissues and three human gastric cancer cell lines (SGC-7901, MGC-803, and BGC-823 cells). After transfection with miR-181a inhibitor, proliferation, apoptosis, migration, and invasion of the SGC-7901 cells were evaluated. Ataxia-telangiectasia mutation (ATM) was predicted as a target gene of miR-181a with bioinformatics analysis, and was verified by lucifersae reporter assay. Expression of ATM protein in HEK293T cells and tissues was measured by Western Blot. Expression of ATM mRNA in HEK293T cells was measured by RT-PCR. Compared with three non-tumour tissues, the expression of miR-181a in three gastric cancer cells was significantly increased by 26.68, 14.83 and 14.96 folds; Compared with Negative Control(NC) and blank groups, transfection of miR-181a inhibitor led to inhibition of SGC7901 cell proliferation, invasion, and migration as well as promotion of apoptosis. A luciferase reporter assay demonstrated that ATM was a direct target of miR-181a, miR-181a mimics transfection down regulated ATM mRNA and protein expression. There was inverse correlation between miR-181a and ATM protein expression in gastric cancer and normal gastric tissues. Our study demonstrates that over-expression of miR-181a might be involved in development of gastric cancer by promoting proliferation and inhibiting apoptosis probably through directly targeting ATM. miR-181a modulation may be a potential strategy for the development of miRNA-based therapy of gastric cancer. © 2014 Arányi Lajos Foundation.

Hou W.,Shantou University | Xu X.,Shantou University | Lei Y.,Peoples Hospital Of New District Longhua Shenzhen | Cao J.,Shantou University | And 4 more authors.
Environmental Science and Pollution Research | Year: 2016

The peak occurrence of Mycoplasma pneumoniae (M. pneumoniae) infections in childhood and haze episodes is concurrent. Together, the prevalence of macrolide-resistant M. pneumoniae varies among countries might also be related to the concentration of ambient fine particulate mass (aerodynamic diameter ≤2.5 μm, PM2.5). Numerous cohort studies have identified consistent associations between ambient PM2.5 and cardiorespiratory morbidity and mortality. PM2.5 is a carrier of the heavy metals. The relationship between PM2.5-associated metals and M. pneumoniae infections in childhood has been increasingly drawing public attention. First, we reviewed original articles and review papers in Pubmed and Web of Science regarding M. pneumoniae and PM2.5-associated metal and analyzed the structural basis of PM2.5-associated metal interaction with M. pneumoniae. Then, the possible mechanisms of action between them were conjectured. Mechanisms of oxidative stress induction and modulation of the host immune system and inflammatory responses via Toll-like receptors (TLRs) and/or the nuclear factor-kappa B (NF-κB) pathway are postulated to be the result of PM2.5-associated metal complex interaction with M. pneumoniae. In addition, a heavy metal effect on M. pneumoniae-expressed community-acquired respiratory distress syndrome (CARDS) toxin, and activation of the aryl hydrocarbon receptor (AhR) and TLRs to induce the differentiation of T helper (Th) cells are also regarded as important reasons for the influence of the heavy metals on the severity of M. pneumoniae pneumonia and the initial onset and exacerbation of M. pneumoniae associated asthma. PM2.5-associated metals via complex mechanisms can exert a great impact on the host through interaction with M. pneumoniae. © 2016 Springer-Verlag Berlin Heidelberg

Bai X.-S.,Peoples Hospital Of New District Longhua Shenzhen | Liu J.-H.,Peoples Hospital Of New District Longhua Shenzhen | Xiao S.-M.,Peoples Hospital Of New District Longhua Shenzhen
Experimental and Therapeutic Medicine | Year: 2014

Agranulocytosis is a rare and serious adverse effect of antithyroid drugs (ATD), in particular methimazole (MMI), and usually develops within 3 months following the start of uninterrupted ATD treatment. Agranulocytosis may also develop for the first time following interruption and subsequent resumption of the same ATD treatment. In this case report, a 27-year-old female, who was treated for thyrotoxicosis with MMI, developed agranulocytosis following the discontinuation of MMI treatment for four months. To the best of our knowledge, this is the first study to report this. The aim of this report is to increase the awareness of physicians of the onset of agranulocytosis when MMI is discontinued, and to demonstrate that MMI should be used with caution.

Su G.,Peoples Hospital Of New District Longhua Shenzhen | Xiang Y.,Peoples Hospital Of New District Longhua Shenzhen | He G.,Peoples Hospital Of New District Longhua Shenzhen | Jiang C.,Peoples Hospital Of New District Longhua Shenzhen | And 3 more authors.
Archives of Medical Research | Year: 2014

Background and Aims: The efficacy of bisphosphonates (BPs) in treating bone loss associated with cancer therapies has been demonstrated in completed studies and ongoing clinical trials. The aim of this study was to investigate the evidence for BP use in treatment of bone loss in postmenopausal, early breast cancer (EBC) patients scheduled to receive aromatase inhibitors (AI). Methods: A comprehensive search for relative articles published until December 2013 was performed. The outcomes included the percentage and absolute change in lumbar spine (LS) and total hip (TH) bone mineral density (BMD). Before pooled meta-analysis, the studies were evaluated for publication bias and heterogeneity. Weighted mean differences (WMDs) and 95% confidence intervals (CIs) were calculated. We also performed subgroup and sensitivity analyses. Results: A total of 11 trials contributed to the analysis. BP was shown to be efficacious in increasing BMD at the LS and TH. WMD in BMD absolute change was 0.21g/cm2 (95% CI, 0.13-0.28) at the LS and 0.27g/cm2 (95% CI, 0.02-0.12) at the TH. WMD in BMD percentage change was 5.42 (95% CI, 4.37-6.48) at the LS and 3.03 (95% CI, 2.01-4.01) at the TH. Subgroup analysis revealed that age difference, interventional duration, types of interventions and BP types were associated with variable effects on BMD at the LS and TH. Conclusions: BPs may protect against bone loss in postmenopausal women with EBC receiving adjuvant AI treatment. © 2014 IMSS.

Discover hidden collaborations